New Delhi [India], November 21: The Organisation of Pharmaceutical Producers of India (OPPI) organized its flagship Annual Summit today at Shangri-La Eros, New Delhi. The summit brought together a distinguished assembly of key Government officials, regulators, industry leaders, member organi
India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook.
The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report by Systematix Research
Commerce Minister Piyush Goyal today said that the latest reforms in the Goods and Services Taxes (GST) in the Pharma sector are huge demand boosters and will benefit both the industry and the end consumers.
A Fitch Wire report said that while Indian corporates generally have low direct exposure to current US tariffs, the pharmaceutical industry remains vulnerable to future trade measures. The US is a key market for Indian drugmakers, and any tariff imposition could ripple across the sector.
Pharmaceutical companies in India are expected to grow steadily at a rate of approximately 10 per cent in FY26, driven by price increases and the launch of new products, according to a report by ICICI Securities.
Pharma sector stocks in the Indian stock market showed strong resilience on Monday despite initial pressure due to the anticipated executive order by U.S. President Donald Trump aimed at cutting prescription drug prices in the United States.
The Indian pharmaceutical market maintained its growth trajectory in April 2025 with a robust 7.8 per cent increase year-over-year growth, translating into an incremental Rs 1,424 Crore sales, according to a report by Pharmatrack.
Habil Khorakiwala, Chairman of pharma company Wockhardt on Friday indicated that any imposition of tariffs on pharma products by the US administration would be counterproductive for the Americans.
Reacting to this, RK Aggarwal (National President, Bulk Drugs Manufacturers Association of India) said that it will have no impact on the pharma sector.